Wim....I know! we probably have the only company which has an NDA within months of getting tentative approval and no value is assigned it. NONE. the current price doesnt even accurately reflect the companies worth on what is known.
in my opinion we should see 6 to 8 million on Seroquel this year and another 6 to 8 on Focalin. especially with the 2 doses being exclusive we saw roughly 4 million on 2 doses back in 2014 when the first 2 were launched so I would suspect the same and then remaining doses by June should easily make the other 2 to 4 million.
so I look at anywhere from 12 to 16 million in revenue and around the same conservative spending of 12 to 14 million. yet we get shorted down to $2.20 Its unreal.
Things needs to change for sure. Unfortunately the history of this management hasn't been very impressive, but I do see where they are making progress. It's the same reason many of you are shall I say die hard holders of IPCI.
Even management said Rexista is their Ace card to prove their technology works. So, that's the kind of thing is that everybody is watching if and when they prove Rexista works and Rexista is of great value. It's like a young man trying to make a name for himself.
haha agreed wimusky...will be an awesome day here when big money arrives for good...then we'll finally be on our road to riches and never looking back except to acknowledge our perseverance in seeing this one through glty
News 
Market Data 
Discover 
